

To those with the means and vision to bring about a better world,

Cancer is a defining health issue of our time. Globally, 18 million people are diagnosed with cancer every year. And 10 million die from the disease.*

The threat posed by the COVID-19 pandemic required a massive global response. Cancer warrants the same urgency, focus and attention.

By 2040 – just 16 years from now – the number of cancer diagnoses globally is predicted to increase by 50%.* This represents an untold amount of pain and suffering to families across the world. Your help can change that.

As leading representatives of the global scientific and research community, we know we're standing at a tipping point that could transform how we understand and overcome cancer.

Fuelled by advances in AI and technology, the next decade presents a unique opportunity to transform the prevention, diagnosis and treatment of cancer for millions. That's why we've come together to ask you to help accelerate a new golden age of cancer research.

With your support, we could develop new blood tests that detect cancer at an earlier stage. We could develop new algorithms that predict your cancer risk so we can halt cancer before it's already begun. And we could develop new and better treatments for children's and young people's cancers so more young patients survive and do so without debilitating, life-long side effects.

Worldwide, the research and scientific community stands ready to make breakthroughs that are within our reach. But a lack of funding is holding us back.

This will take a united and collective effort. It will take scientists, researchers, clinicians and entrepreneurs working together across disciplines and continents. It will take constant technological innovation. It will take radical thinkers who are determined to fast-track progress. But to make this a reality, we need your help.

Philanthropic support allows us to be bolder and to take ideas from lab to clinic faster. It means we can take risks, challenge, innovate, seize opportunities and capitalise on international collaboration to improve and save millions of lives.

**More support means more research.
And more research means less cancer.**

Signed,

Professor Bissan Al-Lazikani

Director of Therapeutics Data Science, MD Anderson Cancer Center

Professor Allan Balmain

Barbara Bass Bakar Distinguished Professorship in Cancer Genetics, University of California San Francisco

Professor Sir John Bell

Regius Professor of Medicine, University of Oxford

Professor Rene Bernards

Professor of Molecular Carcinogenesis, The Netherlands Cancer Institute

Dame Kate Bingham

Managing Partner, SV Health Investors

Professor Catherine Bollard

Director, Center for Cancer and Immunology Research and Professor of Paediatrics, Children's National Hospital and George Washington University

Professor Sir Leszek Borysiewicz FRS FMedSci

Vice Chancellor Emeritus, University of Cambridge

Professor Paul Brennan

Head of the Branch of Genomic Epidemiology, International Agency for Research on Cancer

Professor the Lord Darzi of Denham

Paul Hamlyn Chair of Surgery, Imperial College London

Professor Marcus DaSilva Goncalves

Assistant Professor of Medicine, Weill Cornell Medicine

Professor Johann de Bono

Regius Professor of Cancer Research, Professor of Experimental Cancer Medicine and Honorary Consultant in Medical Oncology, Head of Division of Clinical Studies, Director of the Drug Development Unit and Head of Prostate Cancer Targeted Therapy Group, Institute of Cancer Research

Professor Caroline Dive

Interim Director, CRUK Manchester Institute and Director, CRUK National Biomarker Centre

Professor Stephen Elledge

Gregor Mendel Professor of Genetics and Medicine, Harvard University

Professor Gerard Evan

Professor of Cancer Biology, King's College London and Principal Group Leader, The Francis Crick Institute

Professor Rebecca Fitzgerald

Professor of Cancer Prevention and Director, Early Cancer Institute, University of Cambridge

Iain Foulkes PhD

Executive Director of Research and Innovation, Cancer Research UK and CEO, Cancer Research Horizons

Professor Margaret C Frame PhD FRSE FMedSci OBE

Director, Institute of Genetics and Cancer University of Edinburgh

Dr Judy E. Garber

Chief of the Division of Cancer Genetics and Prevention, Dana-Farber Cancer Institute and Professor of Medicine, Harvard Medical School

Professor Richard Gilbertson FRS FMedSci FRCP EMBO

Li Ka Shing Chair and Head of Department of Oncology, Director, CRUK Cambridge Centre

Professor Gareth Griffiths

Director of Southampton Clinical Trials Unit and Professor of Clinical Trials, University of Southampton

Professor Wendy Garrett

Irene Heinz Given Professor of Immunology and Infectious Diseases, Harvard T. H. Chan School of Public Health and Professor of Medicine, Laureate Institute and Harvard Medical School

Professor Michael N. Hall

Head of Research Group, Biozentrum of the University of Basel

Gregory J Hannon

PhD, FRS, FMedSci, Professor of Cancer Molecular Biology and Director, CRUK Cambridge Institute, University of Cambridge.

Professor David Hunter

Richard Doll Professor of Epidemiology and Medicine and Director Translational Epidemiology Unity, University of Oxford

Professor Sir Stephen P. Jackson

Frederick James Quick Professor of Biology, University of Cambridge and Senior Group Leader, CRUK Cambridge Institute

Professor Tobias Janowitz

Associate Professor, Cancer Center Program Lead, Cold Spring Harbor Laboratory

Professor Mariam Jamal-Hanjani

Professor of Cancer Genomics and Metastasis and Medical Oncology Consultant in Translational Lung Oncology, University College London

Dr Michael Jones

Senior Staff Scientist, Institute of Cancer Research

Professor Nic Jones

Director of Strategic Initiatives, Manchester Cancer Research Centre

Professor Peter Johnson

Professor of Medical Oncology, University of Southampton

Professor Pamela Kearns

Professor of Clinical Paediatric Oncology and Director of the Institute of Cancer and Genomic Sciences, University of Birmingham

Sir David Lane FRS

Professor, Karolinska Institute, Chair, Cancer Grand Challenges Scientific Committee, Chairman, Chugai Pharmabody Pte Ltd.

Nuria López-Bigas

ICREA research professor and Head of the Biomedical Genomics lab, Institute for Research in Biomedicine Barcelona

Professor Jill P. Mesirov

Associate Vice Chancellor for Computational Health Sciences, Professor, Department of Medicine, co-Lead Structural and Functional Genomics, Moores Cancer Center at University of California San Diego

Paul Mischel M.D.

Professor and Vice Chair for Research, Department of Pathology, Institute Scholar, Sarafan ChEM-H, Stanford University

Michelle Mitchell OBE

Chief Executive, Cancer Research UK

Sir Paul Nurse

Director, The Francis Crick Institute

Professor Ketan Patel

Chief Scientist, Cancer Research UK and Director of the MRC Weatherall Institute for Molecular Medicine, University of Oxford

Professor Ruth Plummer MBE

Clinical Professor of Experimental Cancer Medicine, Newcastle University

Professor Sir Bruce Ponder

Emeritus Professor of Oncology, University of Cambridge

Professor C.S. Pramesh

Director, Tata memorial hospital and Co-ordinator, Indian National Cancer Grid

Professor Sir Peter Ratcliffe

Director of Clinical Research, The Francis Crick Institute and Distinguished Scholar, Ludwig Institute for Cancer Research, University of Oxford

Professor Timothy R. Rebbeck

Vincent L. Gregory Jr Professor of Cancer Prevention, Harvard University

Professor Sir Mike Richards

Chair of the UK National Screening Committee and Trustee, Cancer Research UK

Dr Barbara K. Rimer

Professor Emerita Health Behavior, Dean Emerita, UNC Gillings School of Global Public Health

Professor Dame Nancy Rothwell, FRS, FRSB, FMedSci

President and Vice-Chancellor, Professor of Physiology, University of Manchester

Professor Owen Sansom

Director, CRUK Scotland Institute

Dr Lillian Siu

Professor, Medical Oncologist, Princess Margaret Cancer Centre, Director, Phase I Program, University of Toronto

Lord Simon Stevens

Chair, Cancer Research UK

Professor Charles Swanton

Chief Clinician, Cancer Research UK and Deputy Clinical Director, The Francis Crick Institute

Professor Josep Tabernero

Head, Medical Oncology Department and Director, Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital (HUVH)

Professor Karen Vousden

Principal Group Leader, The Francis Crick Institute

Dr Drew Weissman

Director, Penn Institute for RNA Innovation

Professor Eileen White

Deputy Director, Chief Scientific Officer, Rutgers Cancer Institute of New Jersey